ReviewClinical pharmacology and therapeutics2026
The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.
Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor-level treatment strategies beyond monoamine reuptake. The serotonin 5-HT2B receptor (5-HT2BR) is uniquely positioned at the interface of central-antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and clinical literature identified via PubMed and OVID (MEDLINE, Embase, AMED, PsychINFO) databases from inception to September 2025, supplemented by manual searches. Evidence converges that peripheral 5-HT2BR agonism is mechanistically linked to valvular heart disease (VHD) through mitogenic/profibrotic signaling in valve tissue, consistent with historical signals for anorectic agents (e.g., fenfluramine) and ergot-derived dopamine agonists, with supportive but limited data for 3,4-methylenedioxymethamphetamine (MDMA). Classical serotonergic psychedelics bind 5-HT2BRs; therefore, while contemporary dosing regimens are intermittent, cumulative exposure risks remain insufficiently characterized. Conversely, central 5-HT2BR signaling appears bidirectional wherein astrocytic 5-HT2BR activation under sustained serotonergic tone may support metabolic and plasticity programs, whereas neuronal 5-T2BR antagonism can normalize mesolimbic dopamine output and enhance medial prefrontal glutamatergic activity. Clinically, several approved antidepressant adjuncts (e.g., aripiprazole, brexpiprazole, cariprazine) display 5-HT2BR antagonism or inverse agonism and improve depressive symptoms without observed valvular signals in trials. The 5-HT2BR represents a tractable augmentation target for TRD provided that peripheral agonism is rigorously avoided. Consistent with evolving scientific and regulatory safety frameworks, we propose advancing centrally selective, periphery-sparing 5-HT2BR antagonists into biomarker-anchored early cardiac monitoring and preclinical exclusion of valve-cell 5-HT2BR agonism. This framework integrates central efficacy with defined safety boundaries, guiding development of mechanistically informed antidepressant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.